Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global RNA Therapy Clinical Trials Market Snapshot
Chapter 4. Global RNA Therapy Clinical Trials Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. COVID-19 Impact Analysis
Chapter 5. Market Segmentation 1: By Modality Estimates & Trend Analysis
5.1. By Modality & Market Share, 2024 -2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Modality:
5.2.1. RNA interference
5.2.2. Antisense therapy
5.2.3. Messenger RNA
5.2.4. Oligonucleotide, non-antisense, non-RNAi
Chapter 6. Market Segmentation 2: By Clinical Trials Phase Estimates & Trend Analysis
6.1. By Modality & Market Share, 2024 -2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Clinical Trials Phase:
6.2.1. Phase I
6.2.2. Phase II
6.2.3. Phase III
6.2.4. Phase IV
Chapter 7. Market Segmentation 3: By Therapeutic Areas Estimates & Trend Analysis
7.1. By Modality & Market Share, 2024 -2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Therapeutic Areas:
7.2.1. Rare Diseases
7.2.2. Anti-infective
7.2.3. Anticancer
7.2.4. Neurological
7.2.5. Alimentary/Metabolic
7.2.6. Musculoskeletal
7.2.7. Cardiovascular Respiratory
7.2.8. Sensory
7.2.9. Others
Chapter 8. RNA Therapy Clinical Trials Market Segmentation 5: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America RNA Therapy Clinical Trials Market revenue (US$ Million) estimates and forecasts By Modality, 2021-2034
8.1.2. North America RNA Therapy Clinical Trials Market revenue (US$ Million) estimates and forecasts By Clinical Trials Phase, 2021-2034
8.1.3. North America RNA Therapy Clinical Trials Market revenue (US$ Million) estimates and forecasts By Therapeutic Areas, 2021-2034
8.1.4. North America RNA Therapy Clinical Trials Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.1.4.1. U.S.
8.1.4.2. Canada
8.2. Europe
8.2.1. Europe RNA Therapy Clinical Trials Market revenue (US$ Million) By Modality, 2021-2034
8.2.2. Europe RNA Therapy Clinical Trials Market revenue (US$ Million) estimates and forecasts By Clinical Trials Phase, 2021-2034
8.2.3. Europe RNA Therapy Clinical Trials Market revenue (US$ Million) estimates and forecasts By Therapeutic Areas 2021-2034
8.2.4. Europe RNA Therapy Clinical Trials Market revenue (US$ Million) by country, 2021-2034
8.2.4.1. Germany
8.2.4.2. Poland
8.2.4.3. France
8.2.4.4. Italy
8.2.4.5. Spain
8.2.4.6. UK
8.2.4.7. Rest of Europe
8.3. Asia Pacific
8.3.1. Asia Pacific RNA Therapy Clinical Trials Market revenue (US$ Million) by Modality, 2021-2034
8.3.2. Asia Pacific RNA Therapy Clinical Trials Market revenue (US$ Million) estimates and forecasts By Clinical Trials Phase, 2021-2034
8.3.3. Asia Pacific RNA Therapy Clinical Trials Market revenue (US$ Million) estimates and forecasts By Therapeutic Areas, 2021-2034
8.3.4. Asia Pacific RNA Therapy Clinical Trials Market revenue (US$ Million) by country, 2021-2034
8.3.4.1. China
8.3.4.2. India
8.3.4.3. Japan
8.3.4.4. Australia
8.3.4.5. Rest of Asia Pacific
8.4. Latin America
8.4.1. Latin America RNA Therapy Clinical Trials Market revenue (US$ Million) by Modality, 2021-2034
8.4.2. Latin America RNA Therapy Clinical Trials Market revenue (US$ Million) estimates and forecasts Clinical Trials Phase 2021-2034
8.4.3. Latin America RNA Therapy Clinical Trials Market revenue (US$ Million) estimates and forecasts By Therapeutic Areas, 2021-2034
8.4.4. Latin America RNA Therapy Clinical Trials Market revenue (US$ Million) by country, (US$ Million) 2021-2034
8.4.4.1. Brazil
8.4.4.2. Rest of Latin America
8.5. Middle East & Africa
8.5.1. Middle East & Africa RNA Therapy Clinical Trials Market revenue (US$ Million) By Modality, (US$ Million)
8.5.2. Middle East & Africa RNA Therapy Clinical Trials Market revenue (US$ Million) estimates and forecasts By Clinical Trials Phase, 2021-2034
8.5.3. Middle East & Africa RNA Therapy Clinical Trials Market revenue (US$ Million) estimates and forecasts By Therapeutic Areas, 2021-2034
8.5.4. Middle East & Africa RNA Therapy Clinical Trials Market revenue (US$ Million) by country, (US$ Million) 2021-2034South Africa
8.5.4.1. GCC Countries
8.5.4.2. Rest of MEA
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. IQVIA
9.2.2. ICON Plc
9.2.3. Laboratory Corporation of America Holdings
9.2.4. Charles River Laboratories International, Inc.
9.2.5. PAREXEL International Corp.
9.2.6. Syneos Health
9.2.7. Medpace Holdings, Inc.
9.2.8. PPD Inc.
9.2.9. Novotech
9.2.10. Veristat, LLC.
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.